Cerus Corporation Announces Workshop and Abstracts at the 2024 AABB Annual Meeting
Presentations Highlight the Unique Benefits of Real-world Utilization of
INTERCEPT-treated Blood Products,
The following is a select list of
Oral Presentations
-
Sunday, October 20, 2024 – 9:30 a.m.– Acute Kidney Injury to Evaluate Amustaline/Glutathione Pathogen Reduced Red Cells in Cardiac Surgery: Outcomes of the ReCePI Phase III Clinical Trial (Speaker:E. Snyder ) -
Monday, October 21 –9:45 a.m. – Utilizing Sankey Diagrams toQuantify Laboratory Efficiency of INTERCEPT Fibrinogen Complex vs Traditional Cryoprecipitate (Speaker:D. Chen ) -
Monday, October 21, 2024 –2:00 p.m. – Phase IV Trial of Pathogen-reduced Cryoprecipitate vs. Cryoprecipitated AHF to Lower Operative Transfusions (TOPCLOT) in Cardiac Surgery (Speaker:M. Cushing ) -
Monday, October 21, 2024 –2:00 p.m. – HLA Alloimmunization in ReCePI, a Phase III Study of Amustaline/Glutathione Pathogen Reduced RBCs (Speaker:P. Norris ) -
Monday, October 21, 2024 –2:00 p.m. – Treatment-Emergent Antibodies to Amustaline/Glutathione Pathogen-Reduced Red Blood Cells in the ReCePI Phase III Clinical Trial (Speaker:R. Benjamin )
Poster Presentations
Held
- Evaluation of Pathogen Reduction Efficacy in Platelet Concentrates Until End of Shelf-Life with Two Different Automated Bacterial Detection Systems
- Development of a Next Generation Illuminator for Photochemical Inactivation of a Broad Spectrum of Pathogens in Platelet Concentrates
-
Accelerating Treatment Delivery and Reducing Waste with
Implementation of Pathogen Reduced Cryoprecipitated Fibrinogen Complex -
Wastage and Cost Analysis for
INTERCEPT Fibrinogen Complex -
An Analysis of
Anesthesiologist and Transfusion Service Staff Preferences Between Pathogen Reduced Cryoprecipitated Fibrinogen Complex and Conventional Cryoprecipitated AHF - Analysis of Wastage, Savings, and Maternal and Pediatric Outcomes for Pooled Pathogen Reduced Cryoprecipitate versus Conventional Cryoprecipitate
-
Pathogen Reduced Cryoprecipitate Implementation and Assessment of Its Impact in a
Large Academic Medical Center -
Implementation of INTERCEPT Fibrinogen Complex (IFC) for Postpartum Hemorrhage - Evaluation of INTERCEPT RBC Pathogen Reduction in Combination with Irradiation
-
Monday, October 21, 2024 – 7:00 a.m.– Industry Workshop Presented byCerus : Pathogen Reduced Blood Components – Current Experiences and Future Developments with the INTERCEPT® Blood System (Speakers:J. Squires ,C. Ingold ,E. Snyder )
The full program of
ABOUT
INTERCEPT and the INTERCEPT Blood System are trademarks of
View source version on businesswire.com: https://www.businesswire.com/news/home/20241018604249/en/
925-288-6137
Source: